胆碱酯酶抑制剂与谷氨酸受体拮抗剂降血脂药三联疗法应用在血管性痴呆治疗中临床效果研究.docVIP

胆碱酯酶抑制剂与谷氨酸受体拮抗剂降血脂药三联疗法应用在血管性痴呆治疗中临床效果研究 　　[摘要] 目的 该课题旨在探讨血管性痴呆患者应用三联疗法（降血脂药，谷氨酸受体拮抗剂，胆碱酯酶抑制剂）的临床预期效果。 方法 先根据随机数字法对方便选取60例该院2015年2月―2017年3月期间收治的血管性痴呆患者进行分组，再对实验组30例患者采用三联疗法，对照组30例采用常规疗法，对比两组BDS、MMSE与ADL评分。结果 治疗后，实验组MMSE评分（22.31±7.53）分高于对照组的（17.85±7.62）分，BDS（20.33±4.82）分与ADL评分（23.66±7.55）分低于对照组的（24.19±4.24）分、（27.38±6.52）分，差异有统计学意义（P0.05）。结论 血管性痴呆患者的BDS评分与ADL评分可通过三联疗法显著降低，MMSE评分能够得到明显提高，值得推广。 　　[关键词] 血管性痴呆；降血脂药；谷氨酸受体拮抗剂；胆碱酯酶抑制剂；临床疗效 　　[中图分类号] R749 [文献标识码] A [文章编号] 1674-0742（2017）10（b）-0014-03 　　[Abstract] Objective This paper tries to explore the clinical effect of the triple therapy of lowering blood lipid， glutamate receptor antagonist， and cholinesterase inhibitor in patients with vascular dementia. Methods 60 cases of vascular dementia patients admitted in this hospital from February 2015 to March 2017 were convenient selected and divided into two groups according to the random number method， 30 cases in the experimental group were treated with triple therapy， 30 cases in the control group adopted conventional therapy， BDS， MMSE and ADL scores in the two groups were compared. Results After treatment， The MMSE score was （22.31±7.53）points in the experimental group， higher than that of control group of （17.85±7.62）points and BDS was （20.33±4.82）points and ADL score was （23.66±7.55）points， lower than the control group of （24.19±4.24）points， （27.38±6.52）points， and the differences were all statistically significant （P0.05）. Conclusion The BDS score and ADL score of patients with vascular dementia can be significantly reduced by triple therapy， and MMSE score can be significantly improved and it is worth promoting. 　　[Key words] Vascular dementia； Blood lipids； Glutamate receptor antagonist； Cholinesterase inhibitor； Clinical curative effect 　　血管性?V呆主要为智能持续损害的一组慢性综合征，根据发病原因可以分为缺血性血管性痴呆与出血性血管性痴呆[1]。在脑部血管出现多种病变引起脑组织血液供应障碍时，机体脑部功能减弱，很容易发生血管性痴呆。由于患者行为与认知在疾病因素影响下出现程度不一的损害，因此生活质量较差。该次方便择取于2015年2月―2017年3月收治的60例血管性痴呆患者展开研究，探讨三联疗法对其BDS、MMSE与ADL评分的影响，希望能够为临床患者的治疗方案提供参考依据